The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
about
Mirabegron in overactive bladder patients: efficacy review and update on drug safetyEfficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Urinary incontinence in men: current and developing therapy options.A drug safety evaluation of mirabegron in the management of overactive bladder.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).A novel standard to evaluate the impact of therapeutic agents on patient safety - The BURDEN OF THERAPY™©∗.
P2860
Q28072230-78B9B172-E0CA-469E-A114-6D026AC35B2EQ33727733-37622CCF-470A-46F9-8AAA-67716FC5E4F2Q37409521-F65C808F-7187-4B8E-84FD-7CC10BC7B0C0Q38708104-7F0E4BB0-7364-459B-AF52-CA6781152B16Q38776115-E6B1D03F-F033-4C38-A215-BA8D152A6042Q39046374-8C4391B9-4586-486D-A628-DB8703C0C294Q48261630-E592DD1C-DF4E-4CF9-83CE-7CC0B6A94985Q48359190-6E0C3202-3219-4806-BE4E-81F66D978F42Q48719101-ABA1CBE6-9006-4FCB-A380-70B03C57845AQ50890665-634F3415-1E52-4A86-BDF3-50DE5BE151C8Q55312048-87A3A555-BB87-4058-BBB4-BFBD3C4EF58F
P2860
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@ast
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@en
type
label
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@ast
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@en
prefLabel
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@ast
The efficacy and safety of mir ...... randomized, phase IIIb trial.
@en
P2093
P2860
P356
P1476
The efficacy and safety of mir ...... , randomized, phase IIIb trial
@en
P2093
Alex Coppell
BEYOND study group
Emad Siddiqui
Heinz Kölbl
Javier Cambronero
Jose E Batista
Mathilde Kaper
Michael Halaska
Moses Huang
Sender Herschorn
P2860
P304
P356
10.1177/1756287215589250
P577
2015-08-01T00:00:00Z